Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author TISEO, B. C. FMUSP-HC
BONFA, E. FMUSP-HC
BORBA, E. F. FMUSP-HC
MUNHOZ, G. A. FMUSP-HC
WOOD, G. J. A. FMUSP-HC
SROUGI, M. FMUSP-HC
SILVA, C. A. FMUSP-HC
COCUZZA, M. FMUSP-HC
dc.date.issued 2019
dc.identifier.citation LUPUS, v.28, n.1, p.59-65, 2019
dc.identifier.issn 0961-2033
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/30786
dc.description.abstract Objective To evaluate sperm DNA fragmentation analysis in non-azoospermic male systemic lupus erythematosus (SLE) patients. Methods Twenty-eight consecutive male SLE patients (American College of Rheumatology criteria) and 34 healthy controls were evaluated for demographic/exposures data, urological evaluation, hormone profile and sperm analysis (including sperm DNA fragmentation). Clinical features, disease activity/damage scores and treatment were also evaluated. Results The median age (33 (20-52) vs. 36.5 (25-54) years, P = 0.329) and frequency of varicocele (25% vs. 32%, P = 0.183) were similar in SLE patients and healthy controls. Sperm DNA fragmentation showed significantly higher levels of cells class III (44 (9-88) vs. 16.5 (0-80)%, P = 0.001) and cell class IV (10.5 (3-86) vs. 7 (0-36)%, P = 0.039) in SLE. The sperm DNA fragmentation index was also significantly higher in SLE patients (62 (31-97) vs. 25.5 (0-100)%, P < 0.001). Conventional sperm parameters (including sperm count, motility and morphology) were similar in both groups. In SLE patients no correlations were observed between sperm DNA fragmentation index and age, disease duration, Systemic Lupus Erythematosus Disease Activity Index 2000 and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index scores, and cumulative dose of prednisone, hydroxychloroquine, intravenous cyclophosphamide, methotrexate, azathioprine and mycophenolate mofetil (P > 0.05). Further analysis of SLE patients treated with and without intravenous cyclophosphamide showed that total sperm motility was significantly lower in the former group (64% (15-83) vs. 72% (57-86), P = 0.024). The sperm DNA fragmentation index was alike in both groups (52.5 (31-95) vs. 67.5 (34-97)%, P = 0.185). Conclusions To our knowledge, this is the first demonstration that male non-azoospermic SLE patients have increased sperm DNA fragmentation without evident gonadal dysfunction. Intravenous cyclophosphamide does not seem to be a major determinant for this abnormality. Future prospective study is necessary to determine the impact of this alteration in these patients' fertility.
dc.description.sponsorship · Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [BEX-4722/14-0]
· Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2014/14806-0, 2015/03756-4]
· Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [305068/2014-8, 307226/2014-0, 303422/2015-7]
· Federico Foundation
· Nucleo de Apoio a Pesquisa Saude da Crianca e do Adolescente' da USP (NAP-CriAd)
dc.language.iso eng
dc.publisher SAGE PUBLICATIONS LTD
dc.relation.ispartof Lupus
dc.rights restrictedAccess
dc.subject Systemic lupus erythematosus; sperm DNA fragmentation; testicular; sperm; hormone
dc.subject.other rheumatic-diseases; classification; management; fertility; integrity; index; semen
dc.title Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients
dc.type article
dc.rights.holder Copyright SAGE PUBLICATIONS LTD
dc.description.group LIM/17
dc.description.group LIM/36
dc.description.group LIM/55
dc.identifier.doi 10.1177/0961203318815764
dc.identifier.pmid 30509155
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author TISEO, B. C.:HC:ICHC
hcfmusp.author BONFA, E.:FM:MCM
hcfmusp.author BORBA, E. F.:FM:MCM
hcfmusp.author MUNHOZ, G. A.:HC:ICHC
hcfmusp.author WOOD, G. J. A.:FM:
hcfmusp.author SROUGI, M.:FM:MCG
hcfmusp.author SILVA, C. A.:FM:MPE
hcfmusp.author COCUZZA, M.:HC:ICHC
hcfmusp.origem.id WOS:000454147600008
hcfmusp.origem.id 2-s2.0-85059009607
hcfmusp.publisher.city LONDON
hcfmusp.publisher.country ENGLAND
hcfmusp.relation.reference · Bisht Shilpa, 2017, Front Biosci (Schol Ed), V9, P420
· Blumer CG, 2012, BJU INT, V109, P259, DOI 10.1111/j.1464-410X.2011.10240.x
· Cho CL, 2017, TRANSL ANDROL UROL, V6, pS366, DOI 10.21037/tau.2017.07.28
· Donnelly ET, 2000, HUM REPROD, V15, P1552, DOI 10.1093/humrep/15.7.1552
· Farhat J, 2016, REV BRAS REUMATOL, V56, P212, DOI 10.1016/j.rbre.2015.08.005
· Gladman D, 1996, ARTHRITIS RHEUM, V39, P363, DOI 10.1002/art.1780390303
· Gladman DD, 2002, J RHEUMATOL, V29, P288
· Guzick DS, 2001, NEW ENGL J MED, V345, P1388, DOI 10.1056/NEJMoa003005
· Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
· Lu JC, 2018, REPROD BIOL ENDOCRIN, V16, DOI 10.1186/s12958-018-0345-y
· Oliveira JBA, 2018, ANDROLOGIA, V50, DOI 10.1111/and.12889
· Ostensen M, 2011, RHEUMATOLOGY, V50, P657, DOI 10.1093/rheumatology/keq350
· Rabelo CN, 2013, CLIN RHEUMATOL, V32, P109, DOI 10.1007/s10067-012-2083-4
· Shamsi MB, 2011, J ASSIST REPROD GEN, V28, P1073, DOI 10.1007/s10815-011-9631-8
· Silva CA, 2014, AUTOIMMUN REV, V13, P431, DOI 10.1016/j.autrev.2014.01.024
· Silva CAA, 2007, LUPUS, V16, P593, DOI 10.1177/096120330707077538
· Silva CAA, 2002, J RHEUMATOL, V29, P2000
· Silva CA, 2012, CLIN REV ALLERG IMMU, V42, P256, DOI 10.1007/s12016-011-8281-z
· Silva CA, 2010, ARTHRIT CARE RES, V62, P1682, DOI 10.1002/acr.20323
· Silva CA, 2016, EXPERT REV CLIN IMMU, V12, P301, DOI 10.1586/1744666X.2016.1123621
· Soares PMF, 2007, ARTHRITIS RHEUM-US, V56, P2352, DOI 10.1002/art.22660
· Suehiro RM, 2008, RHEUMATOLOGY, V47, P1692, DOI 10.1093/rheumatology/ken338
· Tajar A, 2010, J CLIN ENDOCR METAB, V95, P1810, DOI 10.1210/jc.2009-1796
· Tiseo BC, 2016, INT BRAZ J UROL, V42, P11, DOI 10.1590/S1677-5538.IBJU.2014.0595
· Vecchi AP, 2011, LUPUS, V20, P512, DOI 10.1177/0961203310384121
· WHO, 2010, WHO LAB MAN EX PROC
dc.description.index MEDLINE
dc.identifier.eissn 1477-0962
hcfmusp.citation.scopus 1
hcfmusp.citation.wos 0


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics